Robert Heft, Ph.D.

Robert joined the Parvus Therapeutics Board of Directors in 2017. Dr. Heft currently serves as Chief Executive Officer of Zingenix Ltd., a company focused on gene therapy for severe orphan disorders. Prior to Zingenix, Dr. Heft was Chief Executive Officer and member of the Board of Directors of Enobia Pharma Inc. from 2005 to 2012. Dr. Heft currently serves on the boards of Zingenix Ltd., VisionGate, Inc., Lumos Pharma, Inc., Ra Pharma, and Clementia Pharmaceuticals, Inc. He also serves on the Advisory Board of Sectoral Asset Management. Dr. Heft received a Bachelor of Engineering Degree from McGill University, a Master of Engineering Degree from Cornell University and a Ph.D. from the Massachusetts Institute of Technology in Genetic Engineering and Radiological Sciences.